Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY): 49 pipeline candidates · 6 upcoming catalysts · ~20 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
20.1 months
D/E 0.09 · 0% dilution
Lead: Phase 3
49 candidates
6 upcoming, next in ~196d
0 buys · 14 sells (180d)
A transparent, data-derived signal for Relay Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.4B
Cash
$205.9M
Quarterly Burn
$51.1M
Runway
20.1 mo
Revenue
$3.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (49 candidates)
| Drug | Phase |
|---|---|
| Adavosertib | Phase 2 |
| Afatinib | Phase 3 |
| Afatinib Dimaleate | Phase 3 |
| Alpelisib | Phase 3 |
| AZD1775 | Phase 2 |
| BET Bromodomain Inhibitor ZEN-3694 | Phase 1 |
| Binimetinib | Phase 2 |
| Capivasertib | Phase 3 |
| Ceralasertib | Phase 3 |
| Copanlisib | Phase 2 |
Showing 10 of 49 candidates. Sign up for full pipeline.
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
238
Total value held
$1.68B
| Holder | Shares | Value |
|---|---|---|
| sb investment advisers (uk) ltd | 27,904,963 | $277.7M |
| perceptive advisors llc | 19,502,282 | $194.0M |
| commodore capital lp | 17,000,000 | $169.2M |
| vanguard capital management llc | 14,774,930 | $147.0M |
| blackrock, inc. | 12,975,299 | $129.1M |
| state street corp | 6,233,545 | $62.0M |
| fmr llc | 3,695,431 | $36.8M |
| geode capital management, llc | 3,510,636 | $34.9M |
| balyasny asset management l.p. | 3,039,179 | $30.2M |
| spruce street capital lp | 2,984,125 | $29.7M |
Showing top 10 of 238 institutional holders of Relay Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Relay Therapeutics, Inc.'s pipeline?
Relay Therapeutics, Inc. (RLAY) has 49 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Relay Therapeutics, Inc.'s lead drug candidate?
Relay Therapeutics, Inc.'s most advanced tracked candidate is Adavosertib (Phase 2) for Advanced Lymphoma.
What is Relay Therapeutics, Inc.'s next catalyst?
Relay Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Wit" — expected December 31, 2026.
What is Relay Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Relay Therapeutics, Inc. has approximately 20.1 months of cash runway.
What is Relay Therapeutics, Inc.'s market capitalization?
Relay Therapeutics, Inc.'s market capitalization is approximately $3.4B.
Get the full picture on Relay Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.